Difference between revisions of "Amitriptyline-clomipramine"

From Psychiatrienet
Jump to: navigation, search
Line 3: Line 3:
 
| to = clomipramine  
 
| to = clomipramine  
 
| stop =  
 
| stop =  
* Gradually reduce dosage of amitriptyline to a maximum of 50-100 mg/day.
+
{{stopAmitriptyline1}}
* When a dosage of 50 mg/day is reached, stop administration.
 
 
| start =  
 
| start =  
 
* No wash-out period is needed.  
 
* No wash-out period is needed.  
* Start administration of clomipramine the next day in a normal dosage of 50-75 mg/day.
+
* ''' Day 9: ''' start administration of clomipramine in a normal dosage of 50-75 mg/day.
 
| info =
 
| info =
 
* {{TCAantichol}}
 
* {{TCAantichol}}
{{review}}
 
 
}}
 
}}

Revision as of 13:00, 2 November 2015

Amitriptyline
Type Antidepressant
Group TCA
links
ATC-code N06AA09
Medscape Amitriptyline
PubChem 2160
PubMed Amitriptyline
Kompas (Dutch) Amitriptyline
Wikipedia Amitriptyline
Clomipramine
Type Antidepressant
Group TCA
links
ATC-code N06AA04
Medscape Clomipramine
PubChem 2801
PubMed Clomipramine
Kompas (Dutch) Clomipramine
Wikipedia Clomipramine

Switch medication from amitriptyline to clomipramine.[1] [2]

Nietinrijdenbord.png Stop amitriptyline
  • Before day 1: gradually reduce dosage of amitriptyline to a maximum of 100 mg/day, when this dosage is > 100 mg/day.
  • Day 1: reduce dosage of amitriptyline to 50 mg/day.
  • Day 8: reduce dosage of amitriptyline to 25 mg/day.
  • Day 15: stop administration of amitriptyline.
Eenrichtingbord.png Start clomipramine
  • No wash-out period is needed.
  • Day 9: start administration of clomipramine in a normal dosage of 50-75 mg/day.
Infobord.png More information
  • Both drugs are a TCA with anticholinergic properties, so a switch to a relatively high starting dose can be made.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.